Neuroleptic intolerance in patients with anti-NMDAR encephalitis

Neurology: Neuroimmunology and NeuroInflammation

Volumn 3, Issue 5, 2016, Pages

  Lejuste, Florian ^a   Thomas, Laure ^b,c,d   Picard, Géraldine ^b   Desestret, Virginie ^b,c,d   Ducray, François ^b,c,d   Rogemond, Veronique ^b,c   Psimaras, Dimitri ^b,e   Antoine, Jean Christophe ^b,c,f   Delattre, Jean Yves ^b,e,g   Groc, Laurent ^h   Leboyer, Marion ^a   Honnorat, Jerome ^b,c,d  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b HÔPITAL NEUROLOGIQUE   (France)

^c CNRS   (France)

^d UNIVERSITÉ LYON 1   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^g SORBONNE UNIVERSITÉ   (France)

^h UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85014256868     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000280     Document Type: Article

References (27)

1. Dalmau J, Tüzün E, Wu H, et al. Paraneoplastic anti–N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25–36.
2. Titulaer MJ, McCraken L, Gabilondo I. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157–165.
3. Severance EG, Yolken RH, Eaton WW. Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling. Schizophr Res 2014;176:S0920–S9964.
4. Kayser MS, Dalmau J. The emerging link between autoimmune disorders and neuropsychiatric disease. J Neuropsychiatry Clin Neurosci 2011;23:90–97.
5. Chapman MR, Vause HE. Anti-NMDA receptor encephalitis: diagnosis, psychiatric presentation, and treatment. Am J Psychiatry 2011;168:245–251.
6. Dalmau J, Kayser MS. Anti-NMDA receptor encephalitis in psychiatry. Curr Psychiatry Rev 2011;7:189–193.
7. Armangue T, Titulaer MJ, Malaga I. Pediatric anti-N-methyl-D-aspartate receptor encephalitis: clinical analysis and novel findings in a series of 20 patients. J Pediatr 2013;162:850–856.
8. Zandi MS, Deakin JB, Morris K, et al. Immunotherapy for patients with acute psychosis and serum N-methyl Daspartate receptor (NMDAR) antibodies: a description of a treated case series. Schizophr Res 2014;160:193–195.
9. Zandi MS, Irani SR, Lang B, et al. Disease-relevant auto-antibodies in first episode schizophrenia. J Neurol 2011; 258:686–688.
10. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091–1098.
11. Kayser MS, Titulaer MJ, Gresa-Arribas N, et al. Frequency and characteristics of isolated psychiatric episodes in anti–N-methyl-d-aspartate receptor encephalitis. JAMA Neurol 2013;70:1133–1139.
12. Creten C, Van der Zwann S, Blankespoor RJ, et al. Late onset autism and anti-NMDA-receptor encephalitis. Lancet 2011;378:98.
13. Consoli A, Ronen K, An-Gourfinkel I, et al. Malignant catatonia due to anti-NMDA-receptor encephalitis in a 17-year-old girl: case report. Child Adolesc Psychiatry Ment Health 2011;5:15.
14. Viaccoz A, Desestret V, Ducray F, et al. Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology 2014;82:556–563.
15. Kuo YL, Tsai HF. Anti-NMDA receptor encephalitis with the initial presentation of psychotic mania. J Clin Neurosci 2012;19:896–898.
16. Mohammad SS, Wallace G, Ramanathan S, et al. Antipsychotic-induced akathisia and neuroleptic malignant syndrome in anti-NMDAR encephalitis. Ann Clin Psychiatry 2014;26: 297–298.
17. Punja M, Pomerleau AC, Devlin JJ, et al. Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis: an etiology worth considering in the differential diagnosis of delirium. Clin Toxicol 2013;51:794–797.
18. Caroff SN, Campbell EC. Risk of neuroleptic malignant syndrome in patients with NMDAR encephalitis. Neurol Sci 2015;36:479–480.
19. Gelenberg AJ, Bellinghausen B, Wojcik JD, et al. A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry 1988;145:517–518.
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). Arlington: American Psychiatric Association; 2013.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
22. Carroll BT. The universal field hypothesis of catatonia and neuroleptic malignant syndrome. CNS Spectr 2000;5:26–33.
23. Weller M, Kornhuber JA. Rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome. Med Hypotheses 1992;38:329–333.
24. Kornhuber J, Weller M. Amantadine and the glutamate hypothesis of schizophrenia: experiences in the treatment of neuroleptic malignant syndrome. J Neural Transm Gen Sect 1993;92:57–65.
25. Mikasova L, De Rossi P, Bouchet D, et al. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain 2012;135:1606–1621.
26. Ladepeche L, Dupuis JP, Bouchet D, et al. Single-molecule imaging of the functional crosstalk between surface NMDA and dopamine D1 receptors. Proc Natl Acad Sci U S A 2013;110:18005–18010.
27. Porras G, Berthet A, Dehay B, et al. PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. J Clin Invest 2012;122:3977–3989.